Impotence after Buserelin

The drug belongs to the group of synthetic hormone-like substances. With prolonged use or a one-time overdose, the drug causes a persistent decrease in sexual potency and the development of sexual dysfunction of hormonal origin.

Indications for the use of the substance

Patients are shown to undergo treatment with Buserelin when the following serious pathologies occur:

• hormone-dependent prostate cancer in the late stages of the course. The drug is administered to slow down the production of testosterone in the testes;
• malignant neoplasms in the mammary gland;
• abnormalities in the reproductive system requiring hormone-dependent therapy. The conditions for the use of the drug are usually absolute or relative hyperestrogenic manifestations (uterine fibroids, endometriosis or endometrial hyperplastic processes);
• infertility caused by disruptions in the onset of ovulation. As a result of the use of the drug, doctors can achieve the creation of optimal conditions for the in vitro fertilization program.

Pharmacological action of synthetic hormone

Buserelin has antiandrogenic and antiestrogenic, antigonadotropic and antitumor properties. In terms of their chemical composition, the active components of the drug are similar to hormones that are secreted by the cells of the anterior pituitary gland. The introduction of a medication into the body entails the release of gonadotropins by the pituitary gland. As a result, there is a short-term decrease in the therapeutic concentration of male sex hormones. If the patient takes a pharmacological agent long enough (at least 2 weeks), the gonadotropic function of the pituitary gland is blocked and the secretion of the corresponding hormonal substances stops. There is a persistent decrease in the production of male sex hormones in the ovaries. The content of estradiol in the blood decreases to postmenopausal values. In the presence of advanced stages (3 and 4) of prostate cancer, men receive long-term drug therapy using synthetic hormones. Taking pharmaceutical drugs causes testosterone levels to drop to levels seen after orchiectomy (drug castration). Thus, a man suffers from a temporary loss of sexual potency, spontaneous and adequate erection. As a result of the termination of treatment with Buserelin, a gradual restoration of male sexual performance occurs, the plasma concentration of testosterone and estrogen increases.

Method of application

Buserelin is intended for intramuscular, intranasal and subcutaneous administration. If signs of malignant neoplasms are detected in the prostate, the patient is prescribed a course of intramuscular injections at a dosage of 3.75 mg, the drug is administered every month. In addition, the patient receives 0.5 mg of the drug 3 times a day, which is injected subcutaneously for a week. After the first 7 days of drug therapy, the patient undergoes supportive intranasal therapy with a dosage of 1 mg per day. The drug is administered before the disease progresses. The actual course of treatment continues throughout the life of the man with cancer. Thus, the suppression of testosterone production becomes permanent. Before starting drug treatment by intranasal application of thunder-like substances, the doctor performs a procedure for cleansing the nasal passages if the patient is diagnosed with rhinitis. Patients undergoing hormonal therapy are advised to avoid taking intranasal vasoconstrictor medications for half an hour after the administration of Buserelin. Particular care should be taken when using a pharmacological substance when signs of depressive disorder are detected. The drug can cause a decrease in concentration, so its effect must be taken into account by motor vehicle drivers and persons employed at work that requires maximum concentration and speed of psychomotor reactions.

Contraindications

The drug with hormonal components is not prescribed to patients with individual intolerance, as well as to women during pregnancy and lactation. The decision to limit the dosage of active ingredients is made in the presence of:

• a history of obstructive urinary tract disease
• spinal metastases, as this increases the likelihood of spinal cord compression following an exacerbation of prostate cancer

The substance provokes nausea and headache, sleep disturbances and mood deterioration, decreased libido and angioedema.